
    
      This study will evaluate the safety, reactogenicity, and immunogenicity of a single dose of
      the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of previous
      flavivirus infection.

      Participants will be randomly assigned to receive a single dose of either rZIKV/D4Δ30-713 or
      placebo at study entry (Day 0).

      Study visits will occur on Days 0, 4, 6, 8, 10, 12, 14, 16, 21, 28, 56, 90, 150, and 180.
      Visits may include a physical examination; blood, urine, saliva, vaginal secretions, and
      semen collection; and pregnancy testing.
    
  